An integrated multi-omics study of tumor heterogeneity in patients with treatment-resistant malignant cancer

An integrated multi-omics study of tumor heterogeneity in patients with treatment-resistant malignant cancer - A study of tumor heterogeneity in patients with treatment-resistant malignant cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040181

Enrollment

100

Registered

2020-04-16

Start date

2020-04-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who agree with the content of this study and submit the written consent form

Exclusion criteria

Exclusion criteria: Other than those above

Design outcomes

Primary

Measure	Time frame
1. Gene alterations by DNA sequence 2. Gene expression and fusion genes by tarRNA sequence 3. Epigenomic alterations by micro-array	—

Countries

Japan

Contacts

Public ContactJumpei Takeshita

Kansai Electric Power Hospital Department of Oncology

takeshita.jumpei@e4.kepco.co.jp0664585821

Outcome results